Insulet Corp (PODD): Regina O Sommer , director of Insulet Corp sold 8,019 shares on May 25, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $30.42 per share for a total value of $243,924.34 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 19, 2016, Patrick J Sullivan (CEO) purchased 45,000 shares at $26.98 per share price.On May 16, 2016, Bradley A Thomas (EVP Human Resources) purchased 2,975 shares at $26.63 per share price.Also, On Mar 11, 2016, Daniel J Levangie (President, Drug Delivery) sold 12,299 shares at $30.84 per share price.On Mar 3, 2016, Jessica Hopfield (director) purchased 3,230 shares at $30.91 per share price.
Shares of Insulet Corporation (PODD) ended Wednesday, May 25, 2016 session in red amid volatile trading. The shares closed down -0.28 points or -0.92% at $30.08 with 3,87,405 shares getting traded. Post opening the session at $30.35, the shares hit an intraday low of $29.88 and an intraday high of $30.68 and the price vacillated in this range throughout the day. The company has a market cap of $1,719 M and the number of outstanding shares has been calculated to be 5,71,59,581 shares. The 52-week high of Insulet Corporation is $40.21 and the 52-week low is $23.94.
Insulet Corporation is a medical device company engaged in the development manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System) an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica Massachusetts. Features of the OmniPod System include two-part design no tubing and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod a small lightweight disposable insulin infusion device worn beneath clothing; and the PDM a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated hands-free cannula insertion system.